Altana Signs Up Pharmacia

Despite having little or no presence in the respiratory market, Pharmacia fought off Novartis, Roche and Aventis to win worldwide marketing right to Altana's roflumilast for COPD and asthma--a drug that could become a blockbuster. Altana reckons that Pharmacia, with no similar products of its own that might compete for attention, is strongly committed to roflumilast's success.

The waiting is over. Pharmacia Corp. has emerged as the winner in the battle for one of the industry's most sought-after Phase III products, Altana AG 's PDE 4 inhibitor roflumilast for COPD and asthma [See Deal]. Despite having little or no presence in the respiratory market, the US group fought off Novartis AG , Roche and Aventis SA to win worldwide co-development and marketing rights to a drug that many analysts predict will be a blockbuster. Bullish ones say it could reach €3 billion ($2.7 billion) by 2006.

Pharmacia will pay Altana an upfront fee—estimated at $35 million based on the $.02 charge that Pharmacia will take in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo